Chronic Myelogenous Leukemia Therapy
Research from University of Texas, M. D. Anderson Cancer Center has provided new data on chronic myelogenous leukemia therapy
Published in Blood Weekly, May 31st, 2007
Researchers detail in "Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure," new data in chronic myelogenous leukemia. According to recent research from the United States, "The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies."
"The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-05-31)
More Articles from Blood Weekly
- Cardiology
Clinical Guidelines for Blood Conservation During Cardiac Procedures Developed - Hepatitis C Virus
Cure for Hepatitis C Announced by VCU researcher - Angiology
Actilyse (alteplase) recommended by National Institute for Health and Clinical Excellence for treatment of acute ischaemic stroke - Artificial Organs
HepaLife Completes Private Placement for $2.5 Million - Cancer
Cougar Biotechnology Announces Additions to Clinical Research and Development Team - Coagulation
HemoSense to Supply LabCorp with INRatio System - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
